Skip to main content
NCBI home page
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 2001 Jun 27;15(4):184–187. doi: 10.1002/jcla.1025

p21 gene codon 31 arginine/serine polymorphism: Non‐association with endometriosis

Yao‐Yuan Hsieh 1, Fuu‐Jen Tsai 2,✉, Chi‐Chen Chang 1, Wen‐Chi Chen 3, Chang‐Hai Tsai 2, Horng‐Der Tsai 1, Cheng‐Chieh Lin 4
PMCID: PMC6808162  PMID: 11436200

Abstract

p21, an important regulator of the cell cycle, acts as a mediator of the growth‐suppressing and ‐promoting functions of p53. We aimed to investigate the association between codon 31 polymorphisms of p21 gene and endometriosis. Women were divided into two groups: endometriosis (n = 102) and nonendometriosis (n = 119). The gene polymorphism for p21 codon 31 involved a base change from AGC to AGA and amino acid changes from serine (Ser) to arginine (Arg). Polymorphisms (Ser homozygotes, heterozygotes, Arg homozygotes) between both groups were detected and compared. Associations between the endometriosis and polymorphisms were evaluated. The results revealed that the distributions of different p21 polymorphisms in both groups were nonsignificantly different. The proportions of Ser homozygote/heterozygote/Arg homozygote in endometriosis and nonendometriois populations were 26.5/48.0/25.5% and 17.6/50.4/31.9%, respectively. We concluded the noncorrelation between the endometriosis and the p21 codon 31 polymorphism. p21 gene codon 31 arginine/serine polymorphism is not a useful marker for prediction of endometriosis susceptibility. J. Clin. Lab. Anal. 15:184–187, 2001. © 2001 Wiley‐Liss, Inc.

Keywords: codon 31 polymorphism of p21, endometriosis, polymorphism, p21, single nucleotide polymorphism

REFERENCES

  • 1. Bischoff FZ, Simpson JL. 2000. Heritability and molecular genetic studies of endometriosis. Hum Reprod Update 6:37–44. [DOI] [PubMed] [Google Scholar]
  • 2. Meresman GF, Vighi S, Buquet RA, Contreras‐Ortiz O, Tesone M, Rumi LS. 2000. Apoptosis and expression of Bcl‐2 and Bax in eutopic endometrium from women with endometriosis. Fertil Steril 74:760–766. [DOI] [PubMed] [Google Scholar]
  • 3. Jiang X, Hitchcock A, Bryan EJ, et al. 1996. Microsatellite analysis of endometriosis reveals loss of heterozygosity at candidate ovarian tumor suppressor gene loci. Cancer Res 56:3534–3539. [PubMed] [Google Scholar]
  • 4. el‐Deiry WS, Tokino T, Waldman T, et al. 1995. Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 55:2910–2919. [PubMed] [Google Scholar]
  • 5. Gujuluva CN, Baek JH, Shin KH, Cherrick HM, Park NH. 1994. Effect of UV‐irradiation on cell cycle, viability and the expression of p53, gadd153 and gadd45 genes in normal and HPV‐immortalized human oral keratinocytes. Oncogene 9:1819–1827. [PubMed] [Google Scholar]
  • 6. Harris CC, Hollstein M. 1993. Clinical implications of the p53 tumor‐suppressor gene. N Engl J Med 329:1318–1327. [DOI] [PubMed] [Google Scholar]
  • 7. Li YJ, Laurent‐Puig P, Salmon RJ, Thomas G, Hamelin R. 1995. Polymorphisms and probable lack of mutation in the WAF1‐CIP1 gene in colorectal cancer. Oncogene 10:599–601. [PubMed] [Google Scholar]
  • 8. Li X, Jiao S, Mi R. 1997. Clinical significance of p21H‐ras expression and H‐ras codon 12 mutation in squamous intraepithelial lesion (SIL) and carcinoma of uterine cervix. Chung Hua Chung Liu Tsa Chih 19:306–308. [PubMed] [Google Scholar]
  • 9. Levesque MA, Katsaros D, Massobrio M, et al. 2000. Evidence for a dose‐response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum‐based chemotherapy. Clin Cancer Res 6:3260–3270. [PubMed] [Google Scholar]
  • 10. Jahnson S, Karlsson MG. 2000. Tumor mapping of regional immunostaining for p21, p53, and mdm2 in locally advanced bladder carcinoma. Cancer 89:619–629. [PubMed] [Google Scholar]
  • 11. Cheng L, Lloyd RV, Weaver AL, et al. 2000. The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy. Clin Cancer Res 6:1896–1899. [PubMed] [Google Scholar]
  • 12. Hsu SL, Chen MC, Chou YH, Hwang GY, Yin SC. 1999. Induction of p21(CIP1/Waf1) and activation of p34(cdc2) involved in retinoic acid‐induced apoptosis in human hepatoma Hep3B cells. Exp Cell Res 248:87–96. [DOI] [PubMed] [Google Scholar]
  • 13. Pasz‐Walczak G, Kordek R. 2000. Comparative evaluation of the expression of cell cycle regulating proteins: cyclin D1, p53 and p21 (WAF1) in colorectal cancer. Pol J Pathol 51:63–69. [PubMed] [Google Scholar]
  • 14. Schneider J, Presek P, Braun A, Loffler S, Woitowitz HJ. 2000. Serum ras (p21) as a marker for occupationally derived lung cancer? Clin Chem Lab Med 38:301–305. [DOI] [PubMed] [Google Scholar]
  • 15. Koopmann J, Maintz D, Schild S, et al. 1995. Multiple polymorphisms, but no mutations, in the WAF1/CIP1 gene in human brain tumors. Br J Cancer 72:1230–1233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Harada K, Ogden GR. 2000. An overview of the cell cycle arrest protein, p21(WAF1). Oral Oncol 36:3–7. [DOI] [PubMed] [Google Scholar]
  • 17. Lin CS, Kuo HH, Chen JY, Yang CS, Wang WB. 2000. Epstein‐barr virus nuclear antigen 2 retards cell growth, induces p21(WAF1) expression, and modulates p53 activity post‐translationally. J Mol Biol 303:7–23. [DOI] [PubMed] [Google Scholar]
  • 18. Woodward TA, Klingler PD, Genko PV, Wolfe JT. 2000. Barrett’s esophagus, apoptosis and cell cycle regulation: correlation of p53 with Bax, Bcl‐2 and p21 protein expression. Anticancer Res 20:2427–2432. [PubMed] [Google Scholar]
  • 19. Chen X, Danes C, Lowe M, Herliczek TW, Keyomarsi K. 2000. Activation of the estrogen‐signaling pathway by p21(WAF1/CIP1) in estrogen receptor‐negative breast cancer cells. J Natl Cancer Inst 92:1403–1413. [DOI] [PubMed] [Google Scholar]
  • 20. Kanavaros P, Stefanaki K, Vlachonikolis J, et al. 2000. Expression of p53, p21/waf1, bcl‐2, bax, Rb and Ki67 proteins in Hodgkin’s lymphomas. Histol Histopathol 15:445–453. [DOI] [PubMed] [Google Scholar]
  • 21. Kwok PY, Gu Z. 1999. Single nucleotide polymorphism libraries: why and how are we building them? Mol Med Today 5:538–543. [DOI] [PubMed] [Google Scholar]
  • 22. Collins FS, Guyer MS, Chakravarti A. 1997. Variation on a theme: cataloging human DNA sequence variation. Science 278:1580–1581. [DOI] [PubMed] [Google Scholar]
  • 23. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. 1993. p21 is a universal inhibitor of cyclin kinases. Nature 366:701–704. [DOI] [PubMed] [Google Scholar]
  • 24. Cao L, Yang Z, Li X. 1998. Expression and significance of tumor suppressor gene WAF1 in epithelial ovarian neoplasms. Hunan I Ko Ta Hsueh Hsueh Pao 23:602–604. [PubMed] [Google Scholar]
  • 25. Bankfalvi A, Tory K, Kemper M, et al. 2000. Clinical relevance of immunohistochemical expression of p53‐targeted gene products mdm‐2, p21 and bcl‐2 in breast carcinoma. Pathol Res Pract 196:489–501. [DOI] [PubMed] [Google Scholar]
  • 26. Bahl R, Arora S, Nath N, Mathur M, Shukla NK, Ralhan R. 2000. Novel polymorphism in p21 waf1/cip1 cyclin dependent kinase inhibitor gene: association with human esophageal cancer. Oncogene 19:323–328. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES